American Journal of Cardiology
Volume 105, Issue 1, Supplement , Pages 21A-29A , 4 January 2010

Are There Effects of Renin–Angiotensin System Antagonists Beyond Blood Pressure Control?

  • George Bakris, MD

      Affiliations

    • Corresponding Author InformationAddress for reprints: George Bakris, MD, Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago, 5841 South Maryland Avenue, MC1027, Chicago, Illinois 60637

References 

  1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121:1244–1263
  2. Ruilope L, Kjeldsen SE, De La Sierra A, Mancia G, Ruggenenti P, Stergious GS, et al. The kidney and cardiovascular risk–implications for management: a consensus statement from the European Society of Hypertension. Blood Press. 2007;16:72–79
  3. Muller G, Goettsch C, Morawietz H. Oxidative stress and endothelial dysfunction. Hamostaseologie. 2007;27:5–12
  4. Zhu YC, Zhu YZ, Lu N, Wang MJ, Wang YX, Yao T. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling. Clin Exp Pharmacol Physiol. 2003;30:911–918
  5. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345–352
  6. Ochodnicky P, Vettoretti S, Henning RH, Buikema H, Van Dokkum RP, de Zeeuw D. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. J Nephrol. 2006;19:246–258
  7. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol. 2007;106:26–31
  8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  9. Whitworth JA World Health OrganizationInternational Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983–1992
  10. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187
  11. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4:966–972
  12. Brown MJ. Angiotensin receptor blockers in essential hypertension. Lancet. 1993;342:1374–1375
  13. Kitakaze M, Node K, Takashima S, Minamino T, Kuzuya T, Hori M. Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin converting enzyme in ischemic hearts: role of bradykinin and nitric oxide. Hypertens Res. 2000;23:253–259
  14. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. Role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies. Diabetes. 1997;46:1612–1618
  15. Silverstein RL, Fenves AZ, Ram CV. ARBs and target organ protection: exploring benefits beyond their antihypertensive effects. Postgrad Med. 2004;116:31–3841
  16. Linz W, Wiemer G, Schaper J, Zimmermann R, Nagasawa K, Gohlke P, et al. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Mol Cell Biochem. 1995;147:89–97
  17. Scholkens BA, Linz W, Martorana PA. Experimental cardiovascular benefits of angiotensin-converting enzyme inhibitors: beyond blood pressure reduction. J Cardiovasc Pharmacol. 1991;18(suppl 2):S26–S30
  18. Stier CT, Mahboubi K, DiPippo VA, Levine S, Chander PN. The antiproteinuric action of enalapril in stroke-prone spontaneously hypertensive rats is unrelated to alterations in urinary prostaglandins. J Pharmacol Exp Ther. 1992;260:1410–1415
  19. Okamoto K, Ohta Y, Chikugo T, Shiokawa H, Morita N. Chronic treatment with captopril, SQ29,852, hydralazine and a 33% fish meal diet in malignant stroke-prone spontaneously hypertensive rats. J Hypertens. 1991;9:1105–1117
  20. Brosnan MJ, Hamilton CA, Graham D, Lygate CA, Jardine E, Dominiczak AF. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens. 2002;20:281–286
  21. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrarion CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586–1593
  22. Miyazaki M, Takai S. Anti-atherosclerotic efficacy of olmesartan. J Hum Hypertens. 2002;16(suppl 2):S7–S12
  23. Malmqvist K, Kahan T, Isaksson H, Ostergren J. Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. Blood Press. 2001;10:101–110
  24. Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JM, Tardif JC, et al. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension. 2007;49:1271–1277
  25. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058–2068
  26. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963–1974
  27. O'Rourke MF, Seward JB. Central arterial pressure and arterial pressure pulse: new views entering the second century after Korotkov. Mayo Clin Proc. 2006;81:1057–1068
  28. Jiang XJ, O 'Rourke MF, Zhang YQ, He XY, Liu LS. Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens. 2007;25:1095–1099
  29. Galzerano D, Tammaro P, del Viscovo L, Lama D, Galzerano A, Broglio R, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens. 2005;18:1563–1569
  30. Malmqvist K, Kahan T, Edner M, Bergfeldt L. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol. 2002;90:1107–1112
  31. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577–1578
  32. Bakris G, Burgess E, Weir M, Davidai G, Koval S AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74:364–369
  33. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592
  34. Hilleman DE, Lucas BD. Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction?. Pharmacotherapy. 2004;24:1064–1076
  35. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  36. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559
  37. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. 2008;372:1174–1183Erratum in: Lancet 2008;372:1384
  38. The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluation telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52–61
  39. Turnbull F Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535
  40. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410–1419
  41. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462
  42. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the ASSK trial. JAMA. 2002;288:2421–2431
  43. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? (The LIFE study). Diabetes Care. 2006;29:595–600
  44. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003
  45. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  46. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  47. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30–48
  48. Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Poque J, et al Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet. 2008;372:547–553
  49. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951–958
  50. Verma S, Mamdani MM, Al-Omran M, Melo M, Rouleau J. Angiotensin receptor blockers vs angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results). J Am Soc Hypertens. 2007;1:286–294

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

 This work was supported by Boehringer Ingelheim GmbH.

PII: S0002-9149(09)02485-0

doi: 10.1016/j.amjcard.2009.10.010

American Journal of Cardiology
Volume 105, Issue 1, Supplement , Pages 21A-29A , 4 January 2010

Article Tools

* Image Usage & Resolution